Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 2/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 3/20 | 0.30 |
| ▸ | CCR10 | P46092 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8560363 | 0.89 | CA12 (0.42) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8565364 | 0.86 | LMNA (0.39) | CA12CA1CA2CA9LMNA | |
| SCHEMBL6131660 | 0.81 | CA12 (0.48) | CA12CA1CA2CA9LMNA | |
| SCHEMBL6131605 | 0.80 | CA12 (0.46) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8716992 | 0.79 | CA12 (0.38) | CA12CA1CA2CA9LMNA | |
| SCHEMBL6131569 | 0.78 | LMNA (0.55) | CA12CA1CA2CA9LMNA | |
| SCHEMBL6131614 | 0.78 | LMNA (0.52) | CA12CA1CA2CA9LMNA | |
| SCHEMBL27360986 | 0.76 | CA12 (0.48) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8473394 | 0.76 | LMNA (0.55) | CA12CA1CA2CA9LMNA | |
| SCHEMBL8478713 | 0.74 | LMNA (0.51) | CA12CA1CA2CA9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | CA12 48/4885CA1 22/4885CA2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.